Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Contusugene ladenovec - Gendux/Introgen

Drug Profile

Contusugene ladenovec - Gendux/Introgen

Alternative Names: Ad-p53; Ad5CMV-p53; Adenoviral p53; ADVEXIN; Contusugene ladenovec Gendux; INGN 201; RPR/INGN 201

Latest Information Update: 05 Nov 2009

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gendux; Introgen Therapeutics
  • Developer Gendux; Introgen Therapeutics; National Cancer Institute (USA)
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action Tumour suppressor protein p53 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Head and neck cancer; Li-Fraumeni syndrome

Highest Development Phases

  • Discontinued Bladder cancer; Breast cancer; Bronchiolo-alveolar adenocarcinoma; Glioblastoma; Head and neck cancer; Li-Fraumeni syndrome; Non-small cell lung cancer; Oesophageal cancer; Orofacial cancer; Ovarian cancer; Prostate cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 05 Nov 2009 Discontinued - Clinical-Phase-Unknown for Li-Fraumeni syndrome in USA (IV)
  • 05 Nov 2009 Discontinued - Phase-I for Bladder cancer in USA (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top